Hepatic and Renal Deterioration

How it works

Benefits

Risks & contraindications

Highlighted claims

• The ML-CDSS predicts a patient's risk of hepatic and renal deterioration using blood chemistry data collected at chemotherapy cycles three and four. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• Pharmacists emphasised the clinical value of identifying hepatic and renal risk earlier in the treatment course so that monitoring can be tailored accordingly. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• Behavioural factors such as diet and physical activity, as well as comorbidities, can influence hepatic and renal function but are not captured by the ML-CDSS's blood chemistry-only inputs. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study